Patients with advanced non-small cell lung cancer (NSCLC) who are treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) experience significant clinical benefits. Here, EGFR is linked to non-small cell lung carcinoma.